Korea's Yuhan Signs Deal To Sell Gilead's Viread In Korea
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Yuhan Corp. said it signed an agreement March 30 with Gilead Sciences Inc. to sell the latter's hepatitis B drug Viread (tenofovir) in Korea, beginning in the second half of this year after winning approval from Korea FDA